Erica Palmer

Erica Palmer

Auto-generated profile, based on publicly available information

Erica Palmer

Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, MA 02210, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in Science Advances
Verified
Journal Article
Open access
MSMartin P. Steinbuck
Martin P. Steinbuck
LSLochana M. Seenappa
Lochana M. Seenappa
WZWei Zhan
Wei Zhan
EPErica Palmer
Erica Palmer
MJMimi M. Jung
Mimi M. Jung
PDPeter C. DeMuth
Peter C. DeMuth
Adjuvants are immunoactivators capable of shaping the magnitude and quality of antigen-specific immune responses induced by subunit immunization. Presently, there is an acute need for effective adjuvants that safely induce durable and balanced humoral and cellular responses. Here, we engineered a class of Amphiphile (AMP)–modified, immunostimulatory DNA adjuvants designed for targeted delivery to lymph nodes and enhanced stimulation of TANK-binding kinase 1 (TBK1)–mediated danger-sensing pathways to generate strong adaptive immunity and long-term memory with potent recall potential. AMP-DNA adjuvants induced robust interferon type-I (IFN-I)–driven inflammatory environments in mouse and nonhuman primate (NHP) lymph nodes, leading to significantly enhanced cytokine secretion by polyfunctional CD8 + and CD4 + T cells in multiple tissues, as well as strongly elevated T helper cell 1 (T H 1)–associated and neutralizing antibody responses, in the absence of systemic toxicity. These results demonstrate that AMP modification enables lymph node–targeted DNA adjuvants to potently activate IFN-I signaling to generate substantial cellular and humoral responses crucial for vaccine efficacy.